Illumina, Inc. (NASDAQ:ILMN) Holdings Decreased by Bender Robert & Associates

Bender Robert & Associates lessened its stake in Illumina, Inc. (NASDAQ:ILMN) by 2.2% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 46,164 shares of the life sciences company’s stock after selling 1,061 shares during the period. Illumina accounts for 1.6% of Bender Robert & Associates’ portfolio, making the stock its 19th biggest holding. Bender Robert & Associates’ holdings in Illumina were worth $6,428,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the stock. Brown Brothers Harriman & Co. lifted its stake in shares of Illumina by 460.9% in the 1st quarter. Brown Brothers Harriman & Co. now owns 129 shares of the life sciences company’s stock worth $45,000 after acquiring an additional 106 shares during the period. State of Wyoming bought a new stake in Illumina during the second quarter worth approximately $32,000. Penserra Capital Management LLC acquired a new stake in Illumina in the first quarter worth approximately $64,000. Annis Gardner Whiting Capital Advisors LLC acquired a new stake in Illumina in the third quarter worth approximately $30,000. Finally, VisionPoint Advisory Group LLC boosted its stake in Illumina by 344.6% during the 3rd quarter. VisionPoint Advisory Group LLC now owns 249 shares of the life sciences company’s stock valued at $34,000 after purchasing an additional 193 shares in the last quarter. Institutional investors own 89.42% of the company’s stock.

Illumina Stock Down 1.4 %

Shares of NASDAQ:ILMN traded down $1.60 during midday trading on Thursday, hitting $116.69. 1,810,233 shares of the stock were exchanged, compared to its average volume of 1,763,704. The company has a market capitalization of $18.58 billion, a PE ratio of -16.12 and a beta of 1.19. Illumina, Inc. has a 52-week low of $89.00 and a 52-week high of $232.23. The company has a debt-to-equity ratio of 0.26, a quick ratio of 1.29 and a current ratio of 1.66. The business’s fifty day simple moving average is $134.31 and its two-hundred day simple moving average is $128.15.

Illumina (NASDAQ:ILMN) last posted its quarterly earnings results on Thursday, February 8th. The life sciences company reported $0.14 earnings per share for the quarter, topping analysts’ consensus estimates of $0.01 by $0.13. The company had revenue of $1.12 billion during the quarter, compared to the consensus estimate of $1.09 billion. Illumina had a positive return on equity of 2.20% and a negative net margin of 25.78%. The business’s quarterly revenue was up 3.6% on a year-over-year basis. During the same period last year, the business earned $0.14 EPS. As a group, research analysts predict that Illumina, Inc. will post 0.91 earnings per share for the current fiscal year.

Analysts Set New Price Targets

ILMN has been the subject of several research analyst reports. Barclays upped their price objective on Illumina from $85.00 to $100.00 and gave the company an “underweight” rating in a report on Wednesday, April 10th. HSBC cut shares of Illumina from a “buy” rating to a “hold” rating in a research note on Tuesday, January 16th. StockNews.com raised shares of Illumina from a “hold” rating to a “buy” rating in a research note on Friday, February 16th. OTR Global restated a “mixed” rating on shares of Illumina in a report on Wednesday, March 20th. Finally, Royal Bank of Canada reaffirmed an “outperform” rating and issued a $253.00 price target on shares of Illumina in a report on Tuesday, April 9th. Two research analysts have rated the stock with a sell rating, nine have issued a hold rating and nine have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $167.70.

Insider Buying and Selling at Illumina

In other Illumina news, CEO Jacob Thaysen purchased 7,330 shares of the company’s stock in a transaction dated Thursday, February 22nd. The shares were bought at an average price of $135.29 per share, for a total transaction of $991,675.70. Following the purchase, the chief executive officer now directly owns 14,861 shares in the company, valued at approximately $2,010,544.69. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Corporate insiders own 0.17% of the company’s stock.

Illumina Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.